The impact of HPV vaccination on future cervical screening: A simulation study of two birth cohorts in Denmark

BMJ Open

Volumn 5, Issue 8, 2015, Pages

  Hestbech, Mie Sara ^a   Lynge, Elsebeth ^a   Kragstrup, Jakob ^a   Siersma, Volkert ^a   Baillet, Miguel Vazquez Prada ^a   Brodersen, John ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADULT; ARTICLE; CANCER PREVENTION; COHORT ANALYSIS; DENMARK; FEMALE; FOLLOW UP; GENERAL PRACTITIONER; HUMAN; MAJOR CLINICAL STUDY; MEDICAL INFORMATION; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIMARY HEALTH CARE; RISK REDUCTION; SCREENING TEST; SECONDARY PREVENTION; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VACCINATION; WART VIRUS; EARLY CANCER DIAGNOSIS; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PRIMARY PREVENTION; UTERINE CERVICAL NEOPLASMS; VAGINA SMEAR; VIROLOGY; YOUNG ADULT;

ADULT; DENMARK; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREDICTIVE VALUE OF TESTS; PRIMARY PREVENTION; RISK REDUCTION BEHAVIOR; SECONDARY PREVENTION; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; YOUNG ADULT;

EID: 84941619337     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2015-007921     Document Type: Article

References (37)

1. Lynge E. [Cervical cancer screening]. Ugeskr Laeger 2002;164:171-3.
2. Peirson L, Fitzpatrick-Lewis D, Ciliska D, et al. Screening for cervical cancer: a systematic review and meta-analysis. Syst Rev 2013;2:35.
3. Sasieni P, Adams J. Effect of screening on cervical cancer mortality in England and Wales: analysis of trends with an age period cohort model. BMJ 1999;318:1244-5.
4. Peto J, Gilham C, Fletcher O, et al. The cervical cancer epidemic that screening has prevented in the UK. Lancet 2004;364:249-56.
5. Raffle AE, Alden B, Quinn M, et al. Outcomes of screening to prevent cancer: analysis of cumulative incidence of cervical abnormality and modelling of cases and deaths prevented. BMJ 2003;326:901.
6. Barken SS, Rebolj M, Andersen ES, et al. Frequency of cervical intraepithelial neoplasia treatment in a well-screened population. Int J Cancer 2012;130:2438-44.
7. Carter JR, Ding Z, Rose BR. HPV infection and cervical disease: a review. Aust N Z J Obstet Gynaecol 2011;51:103-8.
8. Sander BB, Rebolj M, Valentiner-Branth P, et al. Introduction of human papillomavirus vaccination in Nordic countries. Vaccine 2012;30:1425-33.
9. Munoz N, Bosch FX, De Sanjosé S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27.
10. Dillner J, Kjaer SK, Wheeler CM, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 2010;341:c3493.
11. Kjaer SK, Sigurdsson K, Iversen OE, et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) 2009;2:868-78.
12. Danish Centre for Health Technology Assessment. Reduction in the risk of cervical cancer by vaccination against human papillomavirus (HPV)-a health technology assessment. Copenhagen: National Board of Health. Ref Type: Report, 2007.
13. Stanley M. Human papillomavirus vaccines versus cervical cancer screening. Clin Oncol (R Coll Radiol) 2008;20:388-94.
14. [Screening for cervical cancer-recommendations]. Copenhagen: National Board of Health, 2012.
15. Statens Serum Institut. HPV-vaccination - tilslutning 2012. EPI-NYT 2013;20. http://www.ssi.dk/Aktuelt/Nyhedsbreve/EPI-NYT/2013/Uge %2020%20-%202013.aspx
16. http://www.statistikbanken. dk/statbank5a/default.asp?w=1280.19-1-2015.
17. Olesen TB, Jensen KE, Munk C, et al. ["Liva"-population survey of female sexual habits]. Ugeskr Laeger 2010;172:3254-9.
18. Jorgensen MJ, Maindal HT, Christensen KS, et al. Sexual behaviour among young Danes aged 15-29 years: a cross-sectional study of core indicators. Sex Transm Infect 2015;91:171-7.
19. Graugaard CL, Rasmussen B, Boisen KA. [Sexual knowledge, attitudes and behavior among young Danes. A questionnaire study]. Ugeskr Laeger 2002;164:4810-14.
20. Dugue PA, Lynge E, Bjerregaard B, et al. Non-participation in screening: the case of cervical cancer in Denmark. Prev Med 2012;54:266-9.
21. Bjerregaard B, Larsen OB. The Danish Pathology Register. Scand J Public Health 2011;39(7 Suppl):72-4.
22. Olivarius NF, Hollnagel H, Krasnik A, et al. The Danish National Health Service Register. A tool for primary health care research. Dan Med Bull 1997;44:449-53.
23. [Screening for cervical cancer-recommendations]. Copenhagen: National Board of Health, 2007.
24. Brotherton JM, Fridman M, May CL, et al. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 2011;377:2085-92.
25. Gertig DM, Brotherton JM, Budd AC, et al. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study. BMC Med 2013;11:227.
26. Danish Qualitydatabase for Cervical Cancer Screening. Danish Qualitydatabase for Cervical Cancer Screening (DKLS) Yearly Report 2012. 2013.
27. Munoz N, Kjaer SK, Sigurdsson K, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst 2010;102:325-39.
28. Crowe E, Pandeya N, Brotherton JM, et al. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia. BMJ 2014;348:g1458.
29. [Study of 11-15-year-olds lifestyle and health behaviour 1997-2008]. 2010. Danish National Board of Health.
30. Ronco G, Van Ballegooijen M, Becker N, et al. Process performance of cervical screening programmes in Europe. Eur J Cancer 2009;45:2659-70.
31. Ostor AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol 1993;12:186-92.
32. McCredie MR, Sharples KJ, Paul C, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol 2008;9:425-34.
33. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-27.
34. Kjaer SK, Breugelmans G, Munk C, et al. Population-based prevalence, type- and age-specific distribution of HPV in women before introduction of an HPV-vaccination program in Denmark. Int J Cancer 2008;123:1864-70.
35. Kjaer SK, Munk C, Junge J, et al. Carcinogenic HPV prevalence and age-specific type distribution in 40, 382 women with normal cervical cytology, ASCUS/LSIL, HSIL, or cervical cancer: what is the potential for prevention? Cancer Causes Control 2014;25:179-89.
36. Baldur-Felskov B, Dehlendorff C, Munk C, et al. Early impact of human papillomavirus vaccination on cervical neoplasia-nationwide follow-up of young Danish women. J Natl Cancer Inst 2014;106: djt460.
37. Mahmud SM, Kliewer EV, Lambert P, et al. Effectiveness of the quadrivalent human papillomavirus vaccine against cervical dysplasia in Manitoba, Canada. J Clin Oncol 2014;32:438-43.